Innovent Biologics (HKSE:01801) Days Sales Outstanding : 52.63 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Days Sales Outstanding?

Innovent Biologics's average Accounts Receivable for the six months ended in Dec. 2023 was HK$1,105 Mil. Innovent Biologics's Revenue for the six months ended in Dec. 2023 was HK$3,833 Mil. Hence, Innovent Biologics's Days Sales Outstanding for the six months ended in Dec. 2023 was 52.63.

The historical rank and industry rank for Innovent Biologics's Days Sales Outstanding or its related term are showing as below:

HKSE:01801' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.62 Med: 61.06 Max: 86.36
Current: 51.14

During the past 8 years, Innovent Biologics's highest Days Sales Outstanding was 86.36. The lowest was 33.62. And the median was 61.06.

HKSE:01801's Days Sales Outstanding is ranked better than
68.42% of 893 companies
in the Biotechnology industry
Industry Median: 72.43 vs HKSE:01801: 51.14

Innovent Biologics's Days Sales Outstanding declined from Dec. 2022 (71.72) to Dec. 2023 (52.63).

Innovent Biologics Days Sales Outstanding Historical Data

The historical data trend for Innovent Biologics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Days Sales Outstanding Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

86.36

33.62

61.06

65.57

46.85

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial										76.73	89.56	71.72	54.14	52.63

Competitive Comparison of Innovent Biologics's Days Sales Outstanding

For the Biotechnology subindustry, Innovent Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Days Sales Outstanding falls into.

Innovent Biologics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Innovent Biologics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (642.411	+	1100.222)	/	2 )	/	6788.068	*	365
=	871.3165					/	6788.068	*	365
=	46.85

Innovent Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1110.736	+	1100.222)	/	2 )	/	3833.19	*	365 / 2
=	1105.479					/	3833.19	*	365 / 2
=	52.63

Innovent Biologics (HKSE:01801) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Innovent Biologics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines